Analysts at Roth Capital assumed coverage on shares of Matinas BioPharma Holdings Inc (NASDAQ:MTNB) in a note issued to investors on Monday, July 10th. The brokerage set a “buy” rating and a $9.00 price target on the stock.
A number of other equities research analysts have also recently commented on MTNB. Maxim Group reissued a “buy” rating and set a $6.00 target price on shares of Matinas BioPharma Holdings in a research report on Monday, March 27th. Aegis reissued a “positive” rating and set a $8.00 target price on shares of Matinas BioPharma Holdings in a research report on Tuesday, March 28th.
Shares of Matinas BioPharma Holdings (NASDAQ MTNB) traded up 14.40% during mid-day trading on Monday, reaching $1.43. 640,549 shares of the company’s stock traded hands. The firm’s market capitalization is $130.70 million. Matinas BioPharma Holdings has a 12-month low of $0.63 and a 12-month high of $3.99. The stock has a 50-day moving average price of $1.66 and a 200 day moving average price of $2.56.
Matinas BioPharma Holdings (NASDAQ:MTNB) last announced its quarterly earnings results on Tuesday, May 16th. The company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.04) by $0.21. Matinas BioPharma Holdings had a negative return on equity of 1,227.85% and a negative net margin of 30,034.20%. The business had revenue of $0.02 million during the quarter. Analysts anticipate that Matinas BioPharma Holdings will post ($0.26) EPS for the current fiscal year.
ILLEGAL ACTIVITY WARNING: “Roth Capital Initiates Coverage on Matinas BioPharma Holdings Inc (NASDAQ:MTNB)” was published by Markets Daily and is owned by of Markets Daily. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of international copyright & trademark laws. The correct version of this piece of content can be accessed at https://www.themarketsdaily.com/2017/08/08/matinas-biopharma-holdings-inc-nasdaqmtnb-now-covered-by-roth-capital-updated-updated-updated.html.
Hedge funds and other institutional investors have recently modified their holdings of the stock. Spark Investment Management LLC bought a new position in shares of Matinas BioPharma Holdings during the first quarter worth about $105,000. Alps Advisors Inc. bought a new position in shares of Matinas BioPharma Holdings during the second quarter worth about $139,000. Schwab Charles Investment Management Inc. bought a new position in shares of Matinas BioPharma Holdings during the second quarter worth about $152,000. Segantii Capital Management Ltd bought a new position in shares of Matinas BioPharma Holdings during the first quarter worth about $166,000. Finally, KCG Holdings Inc. bought a new position in shares of Matinas BioPharma Holdings during the first quarter worth about $193,000.
Matinas BioPharma Holdings Company Profile
Matinas BioPharma Holdings, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in identifying and developing therapeutics for the treatment of serious and life-threatening infections. It is engaged in developing a pipeline of product and development candidates, with an initial focus on serious fungal and bacterial infections.
Receive News & Ratings for Matinas BioPharma Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Matinas BioPharma Holdings Inc and related companies with MarketBeat.com's FREE daily email newsletter.